Value in Oncology, an Interview with Marty Neltner

Podcast

In this exclusive CancerNetwork Blog podcast, nationally regarded healthcare specialist, Marty Neltner, talks about, among other things, how to bring value into an oncology practice.

Marty Neltner

Marty Neltner

In this exclusive Cancer Network podcast, nationally regarded healthcare specialist, Marty Neltner, talks about, among other things, how to bring value into an oncology practice.

Given the current atmosphere in today's challenging healthcare market, community oncology practices need to be especially alert to future trends, one of which is value over volume. In oncology's world, that translates into value over chemo reimbursement.

-Interviewed by Ron Piana

Recent Videos
Better defining which patients with GI cancers are preferred candidates for adoptive cellular therapies may help optimize outcomes.
7 experts are featured in this series.
A consolidated database may allow providers to access information on a patient’s prior treatments and genetic abnormalities all in 1 place.
Experts at Yale Cancer Center highlight ongoing trials intended to improve outcomes across mantle cell lymphoma, T-cell lymphoma, and other populations.
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
7 experts are featured in this series.
7 experts are featured in this series.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
Related Content